Literature DB >> 754992

Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.

K Carlström, N O Lunell, G Zador.   

Abstract

An oral contraceptive containing 20 micrograms of ethinylestradiol and 250 micrograms of levonorgestrel was given to 5 normally menstruating women for two consecutive cycles. Peripheral serum levels of FSH, LH, estradiol-17 beta and progesterone were determined during the treatment period and during two control cycles, one immediately before, and one immediately after treatment. In all 5 women studied there were no LH peaks and no luteal phase levels of progesterone during the treatment cycles indicating complete inhibition of ovulation. 4 of the 5 women showed no biphasic estradiol pattern. Posttreatment control cycles showed reestablished ovulatory pattern in 4 of the 5 subjects.

Entities:  

Keywords:  Biology; Clinical Research; Contraception; Contraceptive Agents; Contraceptive Agents, Estrogen--administraction and dosage; Contraceptive Agents, Female; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents, Progestin; Contraceptive Agents--administraction and dosage; Contraceptive Mode Of Action; Endocrine System; Estradiol--analysis; Estrogens; Ethinyl Estradiol--administraction and dosage; Family Planning; Follicle Stimulating Hormone--analysis; Gonadotropins; Gonadotropins, Pituitary; Hormones; Luteinizing Hormone--analysis; Oral Contraceptives; Oral Contraceptives, Combined; Ovulation Suppression; Physiology; Progestational Hormones; Progesterone--analysis; Research Methodology

Mesh:

Substances:

Year:  1978        PMID: 754992     DOI: 10.1159/000300999

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  1 in total

1.  Sex-specific content preferences for visual sexual stimuli.

Authors:  Heather A Rupp; Kim Wallen
Journal:  Arch Sex Behav       Date:  2008-08-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.